Click Here for 5% Off Your First Aladdin Purchase!
Call +1 (833) 552-7181 or Contact us Earn $25 in coupons on your first order with Aladdin!
Toggle Nav
My Cart
Search
Advanced Search
Menu
Sign In
྾
main product photo

Recombinant Human MMP9 Protein, ＞95%(SDS-PAGE), high purity(Active)

  • ActiBioPure™
  • Animal Free
  • Azide Free
  • Bioactive
  • Carrier Free
  • High performance
  • ≥95%(SDS-PAGE)
Features and benefits
  • Expression System: HEK293
  • Accession #: P14780
  • Protein Tag: C-His
  • Bioactivity: Measured in a cell migration assay using A549 cells. 1 ng/mL of Recombinant Human MMP-9 can effectively induce A549 cells migration. Measured by its ability to cleave the fluorogenic peptide substrate Mca-PLGL-Dpa-AR-NH2. The specific activity is >1100 pm
  • Endotoxin Concentration: <0.1EU/μg
Item Number
rp148898
Grouped product items
SKUSizeAvailabilityPrice Qty
rp148898-10μg
10μg
In stock
$139.90
rp148898-50μg
50μg
In stock
$539.90
rp148898-100μg
100μg
In stock
$799.90
rp148898-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$4,599.90
Add to Wish List Compare
Bulk Order  SDS  DATASHEET

Animal Free, >95%(SDS-PAGE), Active, HEK293 cells, His tag, 20-707 aa

View related series
Accession#:P14780 Gene ID:4318 MMP9

Basic Description

Product NameRecombinant Human MMP9 Protein, ＞95%(SDS-PAGE), high purity
Synonyms92 kDa gelatinase; 92 kDa type IV collagenase; CLG4B; EC 3.4.24; EC 3.4.24.35; Gelatinase B; GELB; macrophage gelatinase; MANDP2; matrix metallopeptidase 9; matrix metalloproteinase 9; matrix metalloproteinase-9; MMP9; MMP-9; type V collagenase
GradeActiBioPure™, Animal Free, Azide Free, Bioactive, Carrier Free, High performance
Product Description

Purity
>95% SDS-PAGE.

Function
May play an essential role in local proteolysis of the extracellular matrix and in leukocyte migration. Could play a role in bone osteoclastic resorption. Cleaves KiSS1 at a Gly- -Leu bond. Cleaves type IV and type V collagen into large C-terminal three quarter fragments and shorter N-terminal one quarter fragments. Degrades fibronectin but not laminin or Pz-peptide.

Background
Matrix metalloproteinases are a family of zinc and calcium dependent endopeptidases with the combined ability to degrade all the components of the extracellular matrix. MMP-9 (gelatinase B) can degrade a broad range of substrates including gelatin, collagen types IV and V, elastin and proteoglycan core protein. It is believed to act synergistically with interstitial collagenase (MMP-1) in the degradation of fibrillar collagens as it degrades their denatured gelatin forms. MMP-9 is produced by keratinocytes, monocytes, macrophages and PMN leukocytes. MMP-9 is present in most cases of inflammatory responses. Structurally, MMP-9 maybe be divided into five distinct domains: a pro-domain which is cleaved upon activation, a gelatin-binding domain consisting of three contiguous fibronectin type II units, a catalytic domain containing the zinc binding site, a proline-rich linker region, and a carboxyl terminal hemopexin-like domain. In addition to the human enzyme, the recombinant mouse MMP-9 is also available.

Specifications & PurityActiBioPure™, Bioactive, Animal Free, Carrier Free, Azide Free, High performance, ≥95%(SDS-PAGE)
Purity＞95%(SDS-PAGE)
BioactivityMeasured in a cell migration assay using A549 cells. 1 ng/mL of Recombinant Human MMP-9 can effectively induce A549 cells migration. Measured by its ability to cleave the fluorogenic peptide substrate Mca-PLGL-Dpa-AR-NH2. The specific activity is >1100 pm
Endotoxin Concentration<0.1EU/μg
Expression SystemHEK293
SpeciesHuman
Amino Acids20-707 aa
SequenceAPRQRQSTLVLFPGDLRTNLTDRQLAEEYLYRYGYTRVAEMRGESKSLGPALLLLQKQLSLPETGELDSATLKAMRTPRCGVPDLGRFQTFEGDLKWHHHNITYWIQNYSEDLPRAVIDDAFARAFALWSAVTPLTFTRVYSRDADIVIQFGVAEHGDGYPFDGKDGLLAHAFPPGPGIQGDAHFDDDELWSLGKGVVVPTRFGNADGAACHFPFIFEGRSYSACTTDGRSDGLPWCSTTANYDTDDRFGFCPSE
Protein TagC-His
Accession #P14780
Predicted molecular weight76 kDa
SDS-PAGE100 kDa

Images

Recombinant Human MMP9 Protein (rp148898) - Protein Bioactivity
Measured in a cell migration assay using A549 cells. 1.0 ng/mL of Recombinant Human MMP-9 (rp148898) can effectively induce A549 cells migration.

Recombinant Human MMP9 Protein (rp148898) - SDS-PAGE
3 μg/lane of Recombinant Human MMP9 Protein was resolved with SDS-PAGE under reducing (R) and non-reducing (N) conditions and visualized by Coomassie® Blue staining, showing a band at 93.7 kDa under reducing conditions and 250.0 & 89.5 kDa under non-reducing conditions.

Product Specifications

FormLyophilized
ReconstitutionReconstitute in water to a concentration of 0.1-1.0 mg/ml.
Storage TempStore at -20°C,Avoid repeated freezing and thawing
Shipped InIce chest + Ice pads
Stability And StorageStore at -20~-80℃ for more than 1 year

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

3 results found

Lot NumberCertificate TypeDateItem
ZJ24F0102348Certificate of AnalysisJan 30, 2024 rp148898
ZJ24F0102352Certificate of AnalysisJan 30, 2024 rp148898
ZJ24F0102346Certificate of AnalysisJan 30, 2024 rp148898

Related Documents

 SDS

 Specification Sheet

References

1. DasGupta S, Murumkar PR, Giridhar R, Yadav MR.  (2009)  Current perspective of TACE inhibitors: a review..  Bioorg Med Chem,  17  (2): (444-59).  [PMID:19095454]
2. Moriyama H, Tsukida T, Inoue Y, Yokota K, Yoshino K, Kondo H, Miura N, Nishimura S.  (2004)  Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents..  J Med Chem,  47  (8): (1930-8).  [PMID:15055993]
3. Wu Y, Li J, Wu J, Morgan P, Xu X, Rancati F, Vallese S, Raveglia L, Hotchandani R, Fuller N et al..  (2012)  Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD)..  Bioorg Med Chem Lett,  22  (1): (138-43).  [PMID:22153340]
4. De Savi C, Pape A, Sawyer Y, Milne D, Davies C, Cumming JG, Ting A, Lamont S, Smith PD, Tart J et al..  (2011)  Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis..  Bioorg Med Chem Lett,  21  (11): (3301-6).  [PMID:21536437]
5. Jin Y, Roycik MD, Bosco DB, Cao Q, Constantino MH, Schwartz MA, Sang QX.  (2013)  Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core..  J Med Chem,  56  (11): (4357-73).  [PMID:23631440]
6. Johnson AR, Pavlovsky AG, Ortwine DF, Prior F, Man CF, Bornemeier DA, Banotai CA, Mueller WT, McConnell P, Yan C et al..  (2007)  Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects..  J Biol Chem,  282  (38): (27781-91).  [PMID:17623656]
7. Georgiadis D, Yiotakis A.  (2008)  Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge..  Bioorg Med Chem,  16  (19): (8781-94).  [PMID:18790648]
8. Kwan JC, Eksioglu EA, Liu C, Paul VJ, Luesch H.  (2009)  Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation..  J Med Chem,  52  (18): (5732-47).  [PMID:19715320]
9. Nuti E, Casalini F, Santamaria S, Gabelloni P, Bendinelli S, Da Pozzo E, Costa B, Marinelli L, La Pietra V, Novellino E et al..  (2011)  Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors..  Eur J Med Chem,  46  (7): (2617-29).  [PMID:21514700]
10. Ruminski PG, Massa M, Strohbach J, Hanau CE, Schmidt M, Scholten JA, Fletcher TR, Hamper BC, Carroll JN, Shieh HS et al..  (2016)  Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis..  J Med Chem,  59  (1): (313-27).  [PMID:26653735]
11. Marshall DC, Lyman SK, McCauley S, Kovalenko M, Spangler R, Liu C, Lee M, O'Sullivan C, Barry-Hamilton V, Ghermazien H et al..  (2015)  Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer..  PLoS ONE,  10  (5): (e0127063).  [PMID:25961845]
12. Jennifer A Jacobsen,Jessica L Fullagar,Melissa T Miller,Seth M Cohen.  (2010-12-30)  Identifying chelators for metalloprotein inhibitors using a fragment-based approach..  Journal of medicinal chemistry,  54  ((2)): (591-602).  [PMID:21189019]
13. Guan-Sheng Jiao,Seongjin Kim,Mahtab Moayeri,Devorah Crown,April Thai,Lynne Cregar-Hernandez,Linda McKasson,Banumathi Sankaran,Axel Lehrer,Teri Wong,Lisa Johns,Stephen A Margosiak,Stephen H Leppla,Alan T Johnson.  (2012-02-22)  Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain..  Bioorganic & medicinal chemistry letters,  22  ((6)): (2242-2246).  [PMID:22342144]
14. Major Gooyit,Wei Song,Kiran V Mahasenan,Katerina Lichtenwalter,Mark A Suckow,Valerie A Schroeder,William R Wolter,Shahriar Mobashery,Mayland Chang.  (2013-09-14)  O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier..  Journal of medicinal chemistry,  56  ((20)): (8139-8150).  [PMID:24028490]
15. Anna M Knapinska,Daniela Dreymuller,Andreas Ludwig,Lyndsay Smith,Vladislav Golubkov,Anjum Sohail,Rafael Fridman,Marc Giulianotti,Travis M LaVoi,Richard A Houghten,Gregg B Fields,Dmitriy Minond.  (2015-07-21)  SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes..  Journal of medicinal chemistry,  58  ((15)): (5808-5824).  [PMID:26192023]
16. Pikul S, Dunham KM, Almstead NG, De B, Natchus MG, Taiwo YO, Williams LE, Hynd BA, Hsieh LC, Janusz MJ, Gu F, Mieling GE..  (2001)  Heterocycle-based MMP inhibitors with P2' substituents..  Bioorg Med Chem Lett,  11  (8): (1009-1013).  [PMID:11327577]
17. Ishida K, Simizu S, Teruya T, Wierzba MK, Osada H..  (2004)  Rational design and synthesis of novel heparan sulfate mimetic compounds as antiadhesive agents..  Bioorg Med Chem Lett,  14  (10): (2505-2509).  [PMID:15109641]
18. Pikul S, McDow Dunham KL, Almstead NG, De B, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Rydel T, Dunaway CM, Gu F, Mieling GE..  (1998)  Discovery of potent, achiral matrix metalloproteinase inhibitors..  J Med Chem,  41  (19): (3568-3571).  [PMID:9733482]
19. Pikul S, McDow Dunham KL, Almstead NG, De B, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Mieling GE..  (1999)  Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases..  J Med Chem,  42  (1): (87-94).  [PMID:9888835]
20. Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Dowty ME, Mieling GE, Janusz MJ, Wang-Weigand S..  (2000)  Design and synthesis of piperazine-based matrix metalloproteinase inhibitors..  J Med Chem,  43  (3): (369-380).  [PMID:10669564]
21. Sawa M, Tsukamoto T, Kiyoi T, Kurokawa K, Nakajima F, Nakada Y, Yokota K, Inoue Y, Kondo H, Yoshino K..  (2002)  New strategy for antedrug application: development of metalloproteinase inhibitors as antipsoriatic drugs..  J Med Chem,  45  (4): (930-936).  [PMID:11831905]
22. Breuer E, Salomon CJ, Katz Y, Chen W, Lu S, Röschenthaler GV, Hadar R, Reich R..  (2004)  Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids..  J Med Chem,  47  (11): (2826-2832).  [PMID:15139760]
23. Mendis E, Kim MM, Rajapakse N, Kim SK..  (2006)  Carboxy derivatized glucosamine is a potent inhibitor of matrix metalloproteinase-9 in HT1080 cells..  Bioorg Med Chem Lett,  16  (12): (3105-3110).  [PMID:16616490]
24. Santos MA, Enyedy EA, Nuti E, Rossello A, Krupenko NI, Krupenko SA..  (2007)  Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs..  Bioorg Med Chem,  15  (3): (1266-1274).  [PMID:17127067]
25. Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV..  (2008)  beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents..  Bioorg Med Chem Lett,  18  (3): (1140-1145).  [PMID:18083558]
26. Li JJ, Nahra J, Johnson AR, Bunker A, O'Brien P, Yue WS, Ortwine DF, Man CF, Baragi V, Kilgore K, Dyer RD, Han HK..  (2008)  Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis..  J Med Chem,  51  (4): (835-841).  [PMID:18251495]
27. Zhang YM, Fan X, Chakaravarty D, Xiang B, Scannevin RH, Huang Z, Ma J, Burke SL, Karnachi P, Rhodes KJ, Jackson PF..  (2008)  1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke..  Bioorg Med Chem Lett,  18  (1): (409-413).  [PMID:17981034]
28. Lo PC, Chen J, Stefflova K, Warren MS, Navab R, Bandarchi B, Mullins S, Tsao M, Cheng JD, Zheng G..  (2009)  Photodynamic molecular beacon triggered by fibroblast activation protein on cancer-associated fibroblasts for diagnosis and treatment of epithelial cancers..  J Med Chem,  52  (2): (358-368).  [PMID:19093877]
29. Watkins GA, Jones EF, Scott Shell M, VanBrocklin HF, Pan MH, Hanrahan SM, Feng JJ, He J, Sounni NE, Dill KA, Contag CH, Coussens LM, Franc BL..  (2009)  Development of an optimized activatable MMP-14 targeted SPECT imaging probe..  Bioorg Med Chem,  17  (2): (653-659).  [PMID:19109023]
30. Balas L, Durand T, Saha S, Johnson I, Mukhopadhyay S..  (2009)  Total synthesis of photoactivatable or fluorescent anandamide probes: novel bioactive compounds with angiogenic activity..  J Med Chem,  52  (4): (1005-1017).  [PMID:19161308]
31. Lauer-Fields JL, Minond D, Chase PS, Baillargeon PE, Saldanha SA, Stawikowska R, Hodder P, Fields GB..  (2009)  High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate..  Bioorg Med Chem,  17  (3): (990-1005).  [PMID:18358729]
32. Claramunt RM, Bouissane L, Cabildo MP, Cornago MP, Elguero J, Radziwon A, Medina C..  (2009)  Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloproteinases..  Bioorg Med Chem,  17  (3): (1290-1296).  [PMID:19128977]
33. Li W, Li J, Wu Y, Wu J, Hotchandani R, Cunningham K, McFadyen I, Bard J, Morgan P, Schlerman F, Xu X, Tam S, Goldman SJ, Williams C, Sypek J, Mansour TS..  (2009)  A selective matrix metalloprotease 12 inhibitor for potential treatment of chronic obstructive pulmonary disease (COPD): discovery of (S)-2-(8-(methoxycarbonylamino)dibenzo[b,d]furan-3-sulfonamido)-3-methylbutanoic acid (MMP408)..  J Med Chem,  52  (7): (1799-1802).  [PMID:19278250]
34. Monovich LG, Tommasi RA, Fujimoto RA, Blancuzzi V, Clark K, Cornell WD, Doti R, Doughty J, Fang J, Farley D, Fitt J, Ganu V, Goldberg R, Goldstein R, Lavoie S, Kulathila R, Macchia W, Parker DT, Melton R, O'Byrne E, Pastor G, Pellas T, Quadros E, Reel N, Roland DM, Sakane Y, Singh H, Skiles J, Somers J, Toscano K, Wigg A, Zhou S, Zhu L, Shieh WC, Xue S, McQuire LW..  (2009)  Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13..  J Med Chem,  52  (11): (3523-3538).  [PMID:19422229]
35. Nuti E, Casalini F, Avramova SI, Santamaria S, Cercignani G, Marinelli L, La Pietra V, Novellino E, Orlandini E, Nencetti S, Tuccinardi T, Martinelli A, Lim NH, Visse R, Nagase H, Rossello A..  (2009)  N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis..  J Med Chem,  52  (15): (4757-4773).  [PMID:19606871]
36. Johnson SL, Chen LH, Barile E, Emdadi A, Sabet M, Yuan H, Wei J, Guiney D, Pellecchia M..  (2009)  Structure-activity relationship studies of a novel series of anthrax lethal factor inhibitors..  Bioorg Med Chem,  17  (9): (3352-3368).  [PMID:19359184]
37. Li W, Li J, Wu Y, Rancati F, Vallese S, Raveglia L, Wu J, Hotchandani R, Fuller N, Cunningham K, Morgan P, Fish S, Krykbaev R, Xu X, Tam S, Goldman SJ, Abraham W, Williams C, Sypek J, Mansour TS..  (2009)  Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma..  J Med Chem,  52  (17): (5408-5419).  [PMID:19725580]
38. Nuti E, Panelli L, Casalini F, Avramova SI, Orlandini E, Santamaria S, Nencetti S, Tuccinardi T, Martinelli A, Cercignani G, D'Amelio N, Maiocchi A, Uggeri F, Rossello A..  (2009)  Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors..  J Med Chem,  52  (20): (6347-6361).  [PMID:19775099]
39. Capková K, Hixon MS, Pellett S, Barbieri JT, Johnson EA, Janda KD..  (2010)  Benzylidene cyclopentenediones: First irreversible inhibitors against botulinum neurotoxin A's zinc endopeptidase..  Bioorg Med Chem Lett,  20  (1): (206-208).  [PMID:19914829]
40. Schnute ME, O'Brien PM, Nahra J, Morris M, Howard Roark W, Hanau CE, Ruminski PG, Scholten JA, Fletcher TR, Hamper BC, Carroll JN, Patt WC, Shieh HS, Collins B, Pavlovsky AG, Palmquist KE, Aston KW, Hitchcock J, Rogers MD, McDonald J, Johnson AR, Munie GE, Wittwer AJ, Man CF, Settle SL, Nemirovskiy O, Vickery LE, Agawal A, Dyer RD, Sunyer T..  (2010)  Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis..  Bioorg Med Chem Lett,  20  (2): (576-580).  [PMID:20005097]
41. Li B, Pai R, Cardinale SC, Butler MM, Peet NP, Moir DT, Bavari S, Bowlin TL..  (2010)  Synthesis and biological evaluation of botulinum neurotoxin a protease inhibitors..  J Med Chem,  53  (5): (2264-2276).  [PMID:20155918]
42. Nuti E, Casalini F, Avramova SI, Santamaria S, Fabbi M, Ferrini S, Marinelli L, La Pietra V, Limongelli V, Novellino E, Cercignani G, Orlandini E, Nencetti S, Rossello A..  (2010)  Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models..  J Med Chem,  53  (6): (2622-2635).  [PMID:20180536]
43. Testero SA, Lee M, Staran RT, Espahbodi M, Llarrull LI, Toth M, Mobashery S, Chang M..  (2011)  Sulfonate-containing thiiranes as selective gelatinase inhibitors..  ACS Med Chem Lett,  2  (2): (177-181).  [PMID:24900296]
44. Shiozaki M, Maeda K, Miura T, Kotoku M, Yamasaki T, Matsuda I, Aoki K, Yasue K, Imai H, Ubukata M, Suma A, Yokota M, Hotta T, Tanaka M, Hase Y, Haas J, Fryer AM, Laird ER, Littmann NM, Andrews SW, Josey JA, Mimura T, Shinozaki Y, Yoshiuchi H, Inaba T..  (2011)  Discovery of (1S,2R,3R)-2,3-dimethyl-2-phenyl-1-sulfamidocyclopropanecarboxylates: novel and highly selective aggrecanase inhibitors..  J Med Chem,  54  (8): (2839-2863).  [PMID:21417219]
45. Gooyit M, Lee M, Schroeder VA, Ikejiri M, Suckow MA, Mobashery S, Chang M..  (2011)  Selective water-soluble gelatinase inhibitor prodrugs..  J Med Chem,  54  (19): (6676-6690).  [PMID:21866961]
46. Neelarapu R, Holzle DL, Velaparthi S, Bai H, Brunsteiner M, Blond SY, Petukhov PA..  (2011)  Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes..  J Med Chem,  54  (13): (4350-4364).  [PMID:21548582]
47. Wang F, Li J, Sinn AL, Knabe WE, Khanna M, Jo I, Silver JM, Oh K, Li L, Sandusky GE, Sledge GW, Nakshatri H, Jones DR, Pollok KE, Meroueh SO..  (2011)  Virtual screening targeting the urokinase receptor, biochemical and cell-based studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis..  J Med Chem,  54  (20): (7193-7205).  [PMID:21851064]
48. Li B, Cardinale SC, Butler MM, Pai R, Nuss JE, Peet NP, Bavari S, Bowlin TL..  (2011)  Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors..  Bioorg Med Chem,  19  (24): (7338-7348).  [PMID:22082667]
49. Roth J, Minond D, Darout E, Liu Q, Lauer J, Hodder P, Fields GB, Roush WR..  (2011)  Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds..  Bioorg Med Chem Lett,  21  (23): (7180-7184).  [PMID:22018790]
50. De Savi C, Morley AD, Nash I, Karoutchi G, Page K, Ting A, Gerhardt S..  (2012)  Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2..  Bioorg Med Chem Lett,  22  (1): (271-277).  [PMID:22153941]
51. Topai A, Breccia P, Minissi F, Padova A, Marini S, Cerbara I..  (2012)  In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors..  Bioorg Med Chem,  20  (7): (2323-2337).  [PMID:22386984]
52. Gege C, Bao B, Bluhm H, Boer J, Gallagher BM, Korniski B, Powers TS, Steeneck C, Taveras AG, Baragi VM..  (2012)  Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis..  J Med Chem,  55  (2): (709-716).  [PMID:22175799]
53. Lee M, Ikejiri M, Klimpel D, Toth M, Espahbodi M, Hesek D, Forbes C, Kumarasiri M, Noll BC, Chang M, Mobashery S..  (2012)  Structure-Activity Relationship for Thiirane-Based Gelatinase Inhibitors..  ACS Med Chem Lett,  3  (6): (490-495).  [PMID:22737278]
54. Nuti E, Casalini F, Santamaria S, Fabbi M, Carbotti G, Ferrini S, Marinelli L, La Pietra V, Novellino E, Camodeca C, Orlandini E, Nencetti S, Rossello A..  (2013)  Selective arylsulfonamide inhibitors of ADAM-17: hit optimization and activity in ovarian cancer cell models..  J Med Chem,  56  (20): (8089-8103).  [PMID:24044434]
55. Maingot L, Elbakali J, Dumont J, Bosc D, Cousaert N, Urban A, Deglane G, Villoutreix B, Nagase H, Sperandio O, Leroux F, Deprez B, Deprez-Poulain R..  (2013)  Aggrecanase-2 inhibitors based on the acylthiosemicarbazide zinc-binding group..  Eur J Med Chem,  69  (244-261).  [PMID:24044937]
56. Day JA, Cohen SM..  (2013)  Investigating the selectivity of metalloenzyme inhibitors..  J Med Chem,  56  (20): (7997-8007).  [PMID:24074025]
57. Williams JD, Khan AR, Cardinale SC, Butler MM, Bowlin TL, Peet NP..  (2014)  Small molecule inhibitors of anthrax lethal factor toxin..  Bioorg Med Chem,  22  (1): (419-434).  [PMID:24290062]
58. Sodji QH, Patil V, Kornacki JR, Mrksich M, Oyelere AK..  (2013)  Synthesis and structure-activity relationship of 3-hydroxypyridine-2-thione-based histone deacetylase inhibitors..  J Med Chem,  56  (24): (9969-9981).  [PMID:24304348]
59. Nara H, Sato K, Naito T, Mototani H, Oki H, Yamamoto Y, Kuno H, Santou T, Kanzaki N, Terauchi J, Uchikawa O, Kori M..  (2014)  Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach..  J Med Chem,  57  (21): (8886-8902).  [PMID:25264600]
60. Spicer TP, Jiang J, Taylor AB, Choi JY, Hart PJ, Roush WR, Fields GB, Hodder PS, Minond D..  (2014)  Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro..  J Med Chem,  57  (22): (9598-9611).  [PMID:25330343]
61. Matusiak N, Castelli R, Tuin AW, Overkleeft HS, Wisastra R, Dekker FJ, Prély LM, Bischoff R, van Waarde A, Dierckx RA, Elsinga PH..  (2015)  A dual inhibitor of matrix metalloproteinases and a disintegrin and metalloproteinases, [¹⁸F]FB-ML5, as a molecular probe for non-invasive MMP/ADAM-targeted imaging..  Bioorg Med Chem,  23  (1): (192-202).  [PMID:25438884]
62. Tseng CH, Tzeng CC, Chiu CC, Hsu CY, Chou CK, Chen YL..  (2015)  Discovery of 2-[2-(5-nitrofuran-2-yl)vinyl]quinoline derivatives as a novel type of antimetastatic agents..  Bioorg Med Chem,  23  (1): (141-148).  [PMID:25467291]
63. Lobo G, Monasterios M, Rodrigues J, Gamboa N, Capparelli MV, Martínez-Cuevas J, Lein M, Jung K, Abramjuk C, Charris J..  (2015)  Synthesis, crystal structure and effect of indeno[1,2-b]indole derivatives on prostate cancer in vitro. Potential effect against MMP-9..  Eur J Med Chem,  96  (281-295).  [PMID:25899333]
64. Behrends M, Wagner S, Kopka K, Schober O, Schäfers M, Kumbhar S, Waller M, Haufe G..  (2015)  New matrix metalloproteinase inhibitors based on γ-fluorinated α-aminocarboxylic and α-aminohydroxamic acids..  Bioorg Med Chem,  23  (13): (3809-3818).  [PMID:25921268]
65. Camodeca C, Nuti E, Tepshi L, Boero S, Tuccinardi T, Stura EA, Poggi A, Zocchi MR, Rossello A..  (2016)  Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models..  Eur J Med Chem,  111  (193-201).  [PMID:26871660]
66. Adhikari N, Halder AK, Mallick S, Saha A, Saha KD, Jha T..  (2016)  Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays..  Bioorg Med Chem,  24  (18): (4291-4309).  [PMID:27452283]
67. Nara H, Sato K, Kaieda A, Oki H, Kuno H, Santou T, Kanzaki N, Terauchi J, Uchikawa O, Kori M..  (2016)  Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors..  Bioorg Med Chem,  24  (23): (6149-6165).  [PMID:27825552]
68. Ouvry G, Berton Y, Bhurruth-Alcor Y, Bonnary L, Bouix-Peter C, Bouquet K, Bourotte M, Chambon S, Comino C, Deprez B, Duvert D, Duvert G, Hacini-Rachinel F, Harris CS, Luzy AP, Mathieu A, Millois C, Pascau J, Pinto A, Polge G, Reitz A, Reversé K, Rosignoli C, Taquet N, Hennequin LF..  (2017)  Identification of novel TACE inhibitors compatible with topical application..  Bioorg Med Chem Lett,  27  (8): (1848-1853).  [PMID:28274635]
69. Choi JY, Fuerst R, Knapinska AM, Taylor AB, Smith L, Cao X, Hart PJ, Fields GB, Roush WR..  (2017)  Structure-Based Design and Synthesis of Potent and Selective Matrix Metalloproteinase 13 Inhibitors..  J Med Chem,  60  (13): (5816-5825).  [PMID:28653849]
70. Ramsbeck D, Hamann A, Schlenzig D, Schilling S, Buchholz M..  (2017)  First insight into structure-activity relationships of selective meprin β inhibitors..  Bioorg Med Chem Lett,  27  (11): (2428-2431).  [PMID:28408220]
71. Li X, Peterson YK, Inks ES, Himes RA, Li J, Zhang Y, Kong X, Chou CJ..  (2018)  Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status..  J Med Chem,  61  (6): (2589-2603).  [PMID:29499113]
72. Senn N, Ott M, Lanz J, Riedl R..  (2017)  Targeted Polypharmacology: Discovery of a Highly Potent Non-Hydroxamate Dual Matrix Metalloproteinase (MMP)-10/-13 Inhibitor..  J Med Chem,  60  (23): (9585-9598).  [PMID:28953404]
73. Lim WC, Kim H, Kim YJ, Choi KC, Lee IH, Lee KH, Kim MK, Ko H..  (2017)  Dioscin suppresses TGF-β1-induced epithelial-mesenchymal transition and suppresses A549 lung cancer migration and invasion..  Bioorg Med Chem Lett,  27  (15): (3342-3348).  [PMID:28610976]
74. Baggio C, Cerofolini L, Fragai M, Luchinat C, Pellecchia M..  (2018)  HTS by NMR for the Identification of Potent and Selective Inhibitors of Metalloenzymes..  ACS Med Chem Lett,  9  (2): (137-142).  [PMID:29456802]
75. Fuerst R, Yong Choi J, Knapinska AM, Smith L, Cameron MD, Ruiz C, Fields GB, Roush WR..  (2018)  Development of matrix metalloproteinase-13 inhibitors - A structure-activity/structure-property relationship study..  Bioorg Med Chem,  26  (18): (4984-4995).  [PMID:30249495]
76. Wang CG, Yao WN, Zhang B, Hua J, Liang D, Wang HS..  (2018)  Lung cancer and matrix metalloproteinases inhibitors of polyphenols from Selaginella tamariscina with suppression activity of migration..  Bioorg Med Chem Lett,  28  (14): (2413-2417).  [PMID:29921475]
77. Stallivieri A, Colombeau L, Devy J, Etique N, Chaintreuil C, Myrzakhmetov B, Achard M, Baros F, Arnoux P, Vanderesse R, Frochot C..  (2018)  New photodynamic molecular beacons (PMB) as potential cancer-targeted agents in PDT..  Bioorg Med Chem,  26  (3): (688-702).  [PMID:29338907]
78. Zheng D, Han L, Qu X, Chen X, Zhong J, Bi X, Liu J, Jiang Y, Jiang C, Huang X..  (2017)  Cytotoxic Fusicoccane-Type Diterpenoids from Streptomyces violascens Isolated from Ailuropoda melanoleuca Feces..  J Nat Prod,  80  (4): (837-844).  [PMID:28206772]
79. Liu B, Trout REL, Chu GH, McGarry D, Jackson RW, Hamrick JC, Daigle DM, Cusick SM, Pozzi C, De Luca F, Benvenuti M, Mangani S, Docquier JD, Weiss WJ, Pevear DC, Xerri L, Burns CJ..  (2020)  Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections..  J Med Chem,  63  (6): (2789-2801).  [PMID:31765155]
80. Jung O, Lee J, Lee YJ, Yun JM, Son YJ, Cho JY, Ryou C, Lee SY..  (2016)  Timosaponin AIII inhibits migration and invasion of A549 human non-small-cell lung cancer cells via attenuations of MMP-2 and MMP-9 by inhibitions of ERK1/2, Src/FAK and β-catenin signaling pathways..  Bioorg Med Chem Lett,  26  (16): (3963-3967).  [PMID:27422337]
81. Baggio C,Velazquez JV,Fragai M,Nordgren TM,Pellecchia M.  (2020)  Therapeutic Targeting of MMP-12 for the Treatment of Chronic Obstructive Pulmonary Disease..  J Med Chem,  63  (21): (12911-12920).  [PMID:33107733]
82. Gona K,Toczek J,Ye Y,Sanzida N,Golbazi A,Boodagh P,Salarian M,Jung JJ,Rajendran S,Kukreja G,Wu TL,Devel L,Sadeghi MM.  (2020)  Hydroxamate-Based Selective Macrophage Elastase (MMP-12) Inhibitors and Radiotracers for Molecular Imaging..  J Med Chem,  63  (23): (15037-15049).  [PMID:33206510]
83. Rocchi D,Blázquez-Barbadillo C,Agamennone M,Laghezza A,Tortorella P,Vicente-Zurdo D,Rosales-Conrado N,Moyano P,Pino JD,González JF,Menéndez JC.  (2021)  Discovery of 7-aminophenanthridin-6-one as a new scaffold for matrix metalloproteinase inhibitors with multitarget neuroprotective activity..  Eur J Med Chem,  210  (113061-113061).  [PMID:33310289]
84. Lenci E,Angeli A,Calugi L,Innocenti R,Carta F,Supuran CT,Trabocchi A.  (2021)  Multitargeting application of proline-derived peptidomimetics addressing cancer-related human matrix metalloproteinase 9 and carbonic anhydrase II..  Eur J Med Chem,  214  (113260-113260).  [PMID:33581552]
85. Triebel, S S, Bläser, J J, Reinke, H H and Tschesche, H H..  (1992)  A 25 kDa alpha 2-microglobulin-related protein is a component of the 125 kDa form of human gelatinase..  FEBS letters,    (21):   [PMID:1281792]
86. Ogata, Y Y, Enghild, J J JJ and Nagase, H H..  (1992)  Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9..  The Journal of biological chemistry,    (25):   [PMID:1371271]
87. Okada, Y Y and 7 more authors..  (1992)  Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymic properties..  The Journal of biological chemistry,    (25):   [PMID:1400481]
88. Kjeldsen, L L and 5 more authors..  (1992)  Human neutrophil gelatinase: a marker for circulating blood neutrophils. Purification and quantitation by enzyme linked immunosorbent assay..  European journal of haematology,      [PMID:1464361]
89. Masure, S S, Proost, P P, Van Damme, J J and Opdenakker, G G..  (1991)  Purification and identification of 91-kDa neutrophil gelatinase. Release by the activating peptide interleukin-8..  European journal of biochemistry,    (1):   [PMID:1645657]
90. Van Ranst, M M and 7 more authors..  (1991)  The cytokine-protease connection: identification of a 96-kD THP-1 gelatinase and regulation by interleukin-1 and cytokine inducers..  Cytokine,      [PMID:1653055]
91. Huhtala, P P and 5 more authors..  (1991)  Complete structure of the human gene for 92-kDa type IV collagenase. Divergent regulation of expression for the 92- and 72-kilodalton enzyme genes in HT-1080 cells..  The Journal of biological chemistry,    (5):   [PMID:1653238]
92. Opdenakker, G G, Masure, S S, Grillet, B B and Van Damme, J J..  (1991)  Cytokine-mediated regulation of human leukocyte gelatinases and role in arthritis..  Lymphokine and cytokine research,      [PMID:1932376]
93. Wilhelm, S M SM and 5 more authors..  (1989)  SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages..  The Journal of biological chemistry,    (15):   [PMID:2551898]
94. Sang, Q X QX, Birkedal-Hansen, H H and Van Wart, H E HE..  (1995)  Proteolytic and non-proteolytic activation of human neutrophil progelatinase B..  Biochimica et biophysica acta,    (6):   [PMID:7669817]
95. Kjeldsen, L L, Johnsen, A H AH, Sengeløv, H H and Borregaard, N N..  (1993)  Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase..  The Journal of biological chemistry,    (15):   [PMID:7683678]
96. Sato, H H and Seiki, M M..  (1993)  Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells..  Oncogene,      [PMID:8426746]
97. Zhang, B B and 5 more authors..  (1999)  Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2-13.1..  Human genetics,      [PMID:10598806]
98. Olson, M W MW and 8 more authors..  (2000)  Characterization of the monomeric and dimeric forms of latent and active matrix metalloproteinase-9. Differential rates for activation by stromelysin 1..  The Journal of biological chemistry,    (28):   [PMID:10644727]
99. Gusman, H H and 5 more authors..  (2001)  Salivary histatin 5 is an inhibitor of both host and bacterial enzymes implicated in periodontal disease..  Infection and immunity,      [PMID:11179305]
100. Brundula, Veronika V, Rewcastle, N Barry NB, Metz, Luanne M LM, Bernard, Claude C CC and Yong, V Wee VW..  (2002)  Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis..  Brain : a journal of neurology,      [PMID:12023318]
101. Rowsell, Siân S and 10 more authors..  (2002)  Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor..  Journal of molecular biology,    (24):   [PMID:12051944]
102. Elkins, Patricia A PA and 7 more authors..  (2002)  Structure of the C-terminally truncated human ProMMP9, a gelatin-binding matrix metalloproteinase..  Acta crystallographica. Section D, Biological crystallography,      [PMID:12077439]
103. Cha, Hyunju H, Kopetzki, Erhard E, Huber, Robert R, Lanzendörfer, Martin M and Brandstetter, Hans H..  (2002)  Structural basis of the adaptive molecular recognition by MMP9..  Journal of molecular biology,    (26):   [PMID:12126625]
104. Reinhardt, D D and 5 more authors..  (2002)  Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP..  Heart (British Cardiac Society),      [PMID:12381651]
105. Takino, Takahisa T and 7 more authors..  (2003)  Cleavage of metastasis suppressor gene product KiSS-1 protein/metastin by matrix metalloproteinases..  Oncogene,    (24):   [PMID:12879005]
106. Zhang, Yuhua Y and 19 more authors..  (2004)  Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis..  The Journal of pharmacology and experimental therapeutics,      [PMID:14718605]
107. Sutton, Timothy A TA and 5 more authors..  (2005)  Minocycline reduces renal microvascular leakage in a rat model of ischemic renal injury..  American journal of physiology. Renal physiology,      [PMID:15353401]
108. Williams, R N RN, Parsons, S L SL, Morris, T M TM, Rowlands, B J BJ and Watson, S A SA..  (2005)  Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models..  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology,      [PMID:15993560]
109. Becker, Daniel P DP and 17 more authors..  (2005)  Synthesis and structure-activity relationships of beta- and alpha-piperidine sulfone hydroxamic acid matrix metalloproteinase inhibitors with oral antitumor efficacy..  Journal of medicinal chemistry,    (20):   [PMID:16220987]
110. Lee, Chanhung Z CZ and 8 more authors..  (2006)  Dose-response effect of tetracyclines on cerebral matrix metalloproteinase-9 after vascular endothelial growth factor hyperstimulation..  Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism,      [PMID:16395286]
111. Fujimoto, Norihiro N and 7 more authors..  (2006)  Extracellular matrix protein 1 inhibits the activity of matrix metalloproteinase 9 through high-affinity protein/protein interactions..  Experimental dermatology,      [PMID:16512877]
112. Machado, Livia S LS and 5 more authors..  (2006)  Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke..  BMC neuroscience,    (17):   [PMID:16846501]
113. Nénan, Soazig S and 6 more authors..  (2007)  Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat..  European journal of pharmacology,    (15):   [PMID:17234180]
114. Hirose, Yuichiro Y and 17 more authors..  (2008)  A functional polymorphism in THBS2 that affects alternative splicing and MMP binding is associated with lumbar-disc herniation..  American journal of human genetics,      [PMID:18455130]
115. Yamamoto, Daisuke D, Takai, Shinji S and Miyazaki, Mizuo M..  (2008)  Inhibitory profiles of captopril on matrix metalloproteinase-9 activity..  European journal of pharmacology,    (7):   [PMID:18501888]
116. Lausch, Ekkehart E and 9 more authors..  (2009)  Mutations in MMP9 and MMP13 determine the mode of inheritance and the clinical spectrum of metaphyseal anadysplasia..  American journal of human genetics,      [PMID:19615667]
117. Kawasaki, Yoshihiro Y and 7 more authors..  (2009)  The adenomatous polyposis coli-associated exchange factors Asef and Asef2 are required for adenoma formation in Apc(Min/+)mice..  EMBO reports,      [PMID:19893577]
118. Radichev, Ilian A IA and 6 more authors..  (2010)  Biochemical characterization of the cellular glycosylphosphatidylinositol-linked membrane type-6 matrix metalloproteinase..  The Journal of biological chemistry,    (21):   [PMID:20308072]
119. Chambers, Mark A MA and 6 more authors..  (2010)  Non-acylated Mycobacterium bovis glycoprotein MPB83 binds to TLR1/2 and stimulates production of matrix metalloproteinase 9..  Biochemical and biophysical research communications,    (24):   [PMID:20800577]
120. Qiu, Zheng Z and 7 more authors..  (2012)  Definition of peptide inhibitors from a synthetic peptide library by targeting gelatinase B/matrix metalloproteinase-9 (MMP-9) and TNF-α converting enzyme (TACE/ADAM-17)..  Journal of enzyme inhibition and medicinal chemistry,      [PMID:21827363]
121. Jeon, Sejin and 22 more authors..  (2020)  Anti-Inflammatory Actions of Soluble Ninjurin-1 Ameliorate Atherosclerosis..  Circulation,    (3):   [PMID:32883094]
122. Chen, X X, Ji, Z L ZL and Chen, Y Z YZ..  (2002)  TTD: Therapeutic Target Database..  Nucleic acids research,    (1):   [PMID:11752352]
123. Levin JI, Chen JM, Cheung K, Cole D, Crago C, Santos ED, Du X, Khafizova G, MacEwan G, Niu C, Salaski EJ, Zask A, Cummons T, Sung A, Xu J, Zhang Y, Xu W, Ayral-Kaloustian S, Jin G, Cowling R, Barone D, Mohler KM, Black RA, Skotnicki JS..  (2003)  Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates..  Bioorg Med Chem Lett,  13  (16): (2799-2803).  [PMID:12873518]

Solution Calculators

Privacy Policy Website Terms of Use Return policy Terms and Conditions of Sale Cookie Policy Sales Policy
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Copyright © 2023-present Aladdin Scientific Corp . All rights reserved.